Arginine, symmetric and asymmetric dimethylarginine levels in the molsidomine treatment of experimental ischemia-reperfusion retinopathy

dc.contributor.authorPolat, Nihat
dc.contributor.authorAtabey Ozer, Murat
dc.contributor.authorParlakpinar, Hakan
dc.contributor.authorAksungur, Zeynep
dc.contributor.authorOzhan, Onural
dc.contributor.authorTurkoz, Yusuf
dc.date.accessioned2021-05-25T11:36:19Z
dc.date.available2021-05-25T11:36:19Z
dc.date.issued2019
dc.departmentİnönü Üniversitesien_US
dc.description.abstractAbstract: This study aimed to evaluate the mean changes in Arginine, Asymmetric Dimethylarginine (ADMA) and Symmetric Dimethylarginine (SDMA) levels in the ischemia/reperfusion (I/R) retinopathy and efficacy of treatment with molsidomine by these levels. Experiments were performed on the New Zealand white rabbits each weighing approximately 2.5 kg. 28 rabbits were assigned to the following 4 groups, group 1 consisted sham, group 2 consisted I/R, group 3 consisted I/R+ treatment with molsidomine, group 4 consisted prophylaxis with molsidomine +I/R. In the group 2, 3 and 4, ischemia was induced by raising the intraocular pressure to 150 mmHg for 60 minutes. After 60 min, the IOP was returned to normal pressure. 4 mg/kg/day molsidomine was administered intraperitoneally four days after I/R in group 3, one day before I/R and three days after I/R in group 4. Arginine, ADMA and SDMA levels were measured on the aqueous humor. The mean arginine levels were 12.3±4.8 ?mol/L in group 1, 12.4±1.4 ?mol/L in group 2, 13.2±2.4 ?mol/L in group 3 and 13.7±4.3 ?mol/L in group 4. No difference was present between the groups (p=0.807). The mean ADMA levels were 2.6±0.8 ?mol/L, 7.3±2.7 ?mol/L, 0.5±0.5 ?mol/L and 2.5±1.0 ?mol/L respectively. Significant increase was present in the group 2 and significant decrease was present in the group 3 (p=0.001). The mean SDMA levels were 1.0±0.3 ?mol/L, 1.8±0.2 ?mol/L, 0.3±0.3 ?mol/L and 1.0±0.4 ?mol/L respectively. Significant increase was present in the group 2 and significant decrease was present in the group 3 (p=0.001). L-Arginine levels were kept steady, ADMA and SDMA values decreased with molsidomine. Four days treatment with molsidomine after I/R may be beneficial more than prophylaxis and three days treatmenten_US
dc.identifier.citationPOLAT N,OZER M. A,PARLAKPİNAR H,AKSUNGUR Z,OZHAN O,TURKOZ Y (2019). Arginine, symmetric and asymmetric dimethylarginine levels in the molsidomine treatment of experimental ischemia-reperfusion retinopathy. Medicine Science, 8(3), 537 - 540. Doi: :10.5455/medscience.2019.08.9008en_US
dc.identifier.doi10.5455/medscience.2019.08.9008en_US
dc.identifier.endpage540en_US
dc.identifier.issn2147-0634
dc.identifier.issue3en_US
dc.identifier.startpage537en_US
dc.identifier.trdizinid363981en_US
dc.identifier.urihttps://doi.org/10.5455/medscience.2019.08.9008
dc.identifier.urihttps://hdl.handle.net/11616/33676
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/363981
dc.identifier.volume8en_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isotren_US
dc.relation.ispartofMedicine Scienceen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleArginine, symmetric and asymmetric dimethylarginine levels in the molsidomine treatment of experimental ischemia-reperfusion retinopathyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
Makale Dosyası.pdf
Boyut:
644.09 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Doyası
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.71 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: